Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Avidity Biosciences and raises the price target from $60 to $65.
October 30, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reaffirmed its Buy rating on Avidity Biosciences and increased the price target from $60 to $65, indicating positive expectations for the stock.
The increase in price target from $60 to $65 by Chardan Capital suggests a positive outlook for Avidity Biosciences, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100